We defined patients who had ever taken metformin
within 90 days after their first prescription for an
erythropoietin-stimulating agent as metformin users,
and we referred to the remaining participants as nonusers.
We defi ned the 91st day after the prescription for
an erythropoietin-stimulating agent as the index date for
study entry.